1. Sulak PJ, Kuehl TJ, Ortiz M et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9.
2. Anderson FD, Hait H. A multicenter randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89–96.
3. Anderson FD, Hait H, Hsiu J et al. Endometrial microstructure after long-term use of a extended-cycle oral contraceptive regimen. Contraception 2005; 71: 55–9.
4. Ludicke F, Johannison E et al. Effect of oral combined contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril 2001; 76: 102–7.
5. Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Nat Cancer Inst 1999; 54: 243–8.
6. Rosenbaum H. Les Progestatifs ESKA, Paris, 2002.
7. Подзолкова Н.М., Кузнецова И.В. Применение марвелона в пролонгированном режиме в качестве противорецидивной терапии гиперпластических процессов эндометрия. Акуш. и гинекол. 2007; 1: 53–7.
8. Kwiecien M, Edelman A, Nicols AMD et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive. A randomized trial. Contraception 2003; 67: 9–13
________________________________________________
1. Sulak PJ, Kuehl TJ, Ortiz M et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9.
2. Anderson FD, Hait H. A multicenter randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89–96.
3. Anderson FD, Hait H, Hsiu J et al. Endometrial microstructure after long-term use of a extended-cycle oral contraceptive regimen. Contraception 2005; 71: 55–9.
4. Ludicke F, Johannison E et al. Effect of oral combined contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril 2001; 76: 102–7.
5. Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Nat Cancer Inst 1999; 54: 243–8.
6. Rosenbaum H. Les Progestatifs ESKA, Paris, 2002.
7. Подзолкова Н.М., Кузнецова И.В. Применение марвелона в пролонгированном режиме в качестве противорецидивной терапии гиперпластических процессов эндометрия. Акуш. и гинекол. 2007; 1: 53–7.
8. Kwiecien M, Edelman A, Nicols AMD et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive. A randomized trial. Contraception 2003; 67: 9–13
Авторы
И.В.Кузнецова
Кафедра акушерства и гинекологии №1 лечебного факультета ММА им. И.М.Сеченова